Obesity treatment: novel peripheral targets

Our knowledge of the complex mechanisms underlying energy homeostasis has expanded enormously in recent years. Food intake and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including cholecystokinin, glucagon-like peptide-1, peptide YY, oxyntomodulin, amylin, pancreatic polypeptide and ghrelin, have been shown to play an important role in regulating short-term food intake. These hormones therefore represent potential targets in the development of novel anti-obesity drugs. This review focuses on the role of gut hormones in shortand long-term regulation of food intake, and on the current state of development of gut hormone-based obesity therapies.

[1]  S. Bloom,et al.  Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. , 2009, Endocrinology.

[2]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.

[3]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[4]  K. Ho,et al.  Faculty Opinions recommendation of Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. , 2009 .

[5]  D. Russell-Jones Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue , 2009, Molecular and Cellular Endocrinology.

[6]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[7]  L. Aronne,et al.  Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity , 2008, Diabetes Care.

[8]  M. Monteiro,et al.  No evidence of an additive inhibitory feeding effect following PP and PYY3−36 administration , 2008, International Journal of Obesity.

[9]  K. Elkind-Hirsch,et al.  Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. , 2008, The Journal of clinical endocrinology and metabolism.

[10]  Christian Weyer,et al.  Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.

[11]  SyedRizwanudden Ahmad,et al.  Exenatide and rare adverse events. , 2008, The New England journal of medicine.

[12]  M. Ruiz‐Gayo,et al.  Leptin-mediated hypothalamic pathway of cholecystokinin (CCK-8) to regulate body weight in free-feeding rats. , 2008, Endocrinology.

[13]  Lawrence A Leiter,et al.  Stimulation of Cholecystokinin‐A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients , 2008, Clinical pharmacology and therapeutics.

[14]  S. Bloom,et al.  Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake , 2008, Annals of clinical biochemistry.

[15]  C. Weyer,et al.  Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. , 2007, Endocrinology.

[16]  D. Ffytche,et al.  PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans , 2007, Nature.

[17]  J. Livingston,et al.  Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. , 2007, Endocrinology.

[18]  Astrid A. Ortiz,et al.  Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. , 2007, Journal of medicinal chemistry.

[19]  R. Quirion,et al.  Distribution of Peripherally Injected Peptide YY ([125I] PYY (3–36)) and Pancreatic Polypeptide ([125I] hPP) in the CNS: Enrichment in the Area Postrema , 2007, Journal of Molecular Neuroscience.

[20]  H. Jang,et al.  Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 , 2007, Proceedings of the National Academy of Sciences.

[21]  Steven C Hunt,et al.  Long-term mortality after gastric bypass surgery. , 2007, The New England journal of medicine.

[22]  M. Galyean,et al.  Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. , 2007, Domestic animal endocrinology.

[23]  P. Chelikani,et al.  Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[24]  S. Heymsfield,et al.  Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. , 2007, The Journal of clinical endocrinology and metabolism.

[25]  G. Frost,et al.  Low-dose pancreatic polypeptide inhibits food intake in man , 2007, British Journal of Nutrition.

[26]  S. Majumdar,et al.  Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.

[27]  H. Inoue,et al.  Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs. , 2006, The Journal of endocrinology.

[28]  M. Fujimiya,et al.  Peptide YY3‐36 and pancreatic polypeptide suppress food intake , 2006, Journal of gastroenterology and hepatology.

[29]  Jimmy D Bell,et al.  Critical role for peptide YY in protein-mediated satiation and body-weight regulation. , 2006, Cell metabolism.

[30]  E. Zorrilla,et al.  Vaccination against weight gain , 2006, Proceedings of the National Academy of Sciences.

[31]  C. Seva,et al.  Cholecystokinin and gastrin receptors. , 2006, Physiological reviews.

[32]  Dennis D. Kim,et al.  Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus , 2006, Diabetes, obesity & metabolism.

[33]  G. Ferzli,et al.  Laparoscopic gastric bypass is superior to adjustable gastric band in super morbidly obese patients: A prospective, comparative analysis. , 2006, Archives of surgery.

[34]  C. Mcintosh,et al.  Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY , 2006, Diabetologia.

[35]  T. Schwartz,et al.  The PP-fold solution structure of human polypeptide YY and human PYY3-36 as determined by NMR. , 2006, Biochemistry.

[36]  D. Cottam,et al.  A Case-Controlled Matched-Pair Cohort Study of Laparoscopic Roux-en-Y Gastric Bypass and Lap-Band® Patients in a Single US Center with Three-Year Follow-up , 2006, Obesity surgery.

[37]  Josep Vidal,et al.  Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. , 2006, The Journal of clinical endocrinology and metabolism.

[38]  G. Frost,et al.  Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial , 2006, International Journal of Obesity.

[39]  S. Klußmann,et al.  Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. , 2006, Endocrinology.

[40]  P. S. Denker,et al.  Exenatide (exendin-4)-induced pancreatitis: a case report. , 2006, Diabetes care.

[41]  S. Bloom,et al.  The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat , 2006, International Journal of Obesity.

[42]  J. Holst,et al.  Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs , 2006, Diabetologia.

[43]  R. Batterham,et al.  Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.

[44]  Mohammad A Ghatei,et al.  Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. , 2005, Endocrinology.

[45]  R. L. Clark,et al.  Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. , 2005, Diabetes.

[46]  D. Allison,et al.  PYY3‐36 as an anti‐obesity drug target , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[47]  Christoph Beglinger,et al.  Effect of peptide YY3-36 on food intake in humans. , 2005, Gastroenterology.

[48]  J. Holst,et al.  A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. , 2005, The Journal of clinical endocrinology and metabolism.

[49]  D. Drucker,et al.  Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. , 2005, Endocrinology.

[50]  Karim Meeran,et al.  Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. , 2005, Diabetes.

[51]  B. Klapp,et al.  Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats , 2005, Gut.

[52]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[53]  K. Toshinai,et al.  The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.

[54]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[55]  P. Chelikani,et al.  Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. , 2005, Endocrinology.

[56]  T. Moran,et al.  Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[57]  J. Griffith,et al.  Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. , 2005, JAMA.

[58]  B. Beck,et al.  Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. , 2004, Life sciences.

[59]  G. Frost,et al.  Ghrelin increases food intake in obese as well as lean subjects , 2004, International Journal of Obesity.

[60]  O G Kolterman,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[61]  M. Tschöp,et al.  Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. Beglinger,et al.  Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[63]  M. Vanderpump,et al.  Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[64]  D. Drucker,et al.  Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. , 2004, Gastroenterology.

[65]  A. Young,et al.  Effects of PYY[3–36] in rodent models of diabetes and obesity , 2004, International Journal of Obesity.

[66]  D. Allison,et al.  Physiology: Does gut hormone PYY3–36 decrease food intake in rodents? , 2004, Nature.

[67]  M. Low,et al.  Physiology: Does gut hormone PYY3–36 decrease food intake in rodents? (reply) , 2004, Nature.

[68]  N. Martin,et al.  Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY3–36 but resistant to ghrelin , 2004, International Journal of Obesity.

[69]  Mohammad A Ghatei,et al.  Peripheral oxyntomodulin reduces food intake and body weight gain in rats. , 2004, Endocrinology.

[70]  J Dixon,et al.  Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  T. Kigoshi,et al.  Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells , 2004, Autonomic Neuroscience.

[72]  S. O’Rahilly,et al.  Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. , 2003, Biochemical and biophysical research communications.

[73]  T. Schwartz,et al.  High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist. , 2003, Molecular endocrinology.

[74]  Mohammad A Ghatei,et al.  Oxyntomodulin suppresses appetite and reduces food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[75]  Mohammad A Ghatei,et al.  Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.

[76]  D. Ryan,et al.  Short-Term Food Restriction and Refeeding Alter Expression of Genes Likely Involved in Brain Glucosensing , 2003, Experimental biology and medicine.

[77]  G. Frost,et al.  Pancreatic polypeptide reduces appetite and food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[78]  M. Fujimiya,et al.  Antagonism of ghrelin receptor reduces food intake and body weight gain in mice , 2003, Gut.

[79]  M. Fujimiya,et al.  Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. , 2003, Gastroenterology.

[80]  P. Hipskind,et al.  Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes 1 , 2003, Experimental biology and medicine.

[81]  C. Weyer,et al.  Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.

[82]  K. Grove,et al.  Orexin Neurons Express a Functional Pancreatic Polypeptide Y4 Receptor , 2003, The Journal of Neuroscience.

[83]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.

[84]  K. Kangawa,et al.  Ghrelin immunoreactivity in human plasma is suppressed by somatostatin , 2002, Clinical endocrinology.

[85]  M. Papotti,et al.  Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. , 2002, The Journal of clinical endocrinology and metabolism.

[86]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[87]  Mohammad A Ghatei,et al.  Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. , 2002, American journal of physiology. Endocrinology and metabolism.

[88]  S. Bloom,et al.  Food fails to suppress ghrelin levels in obese humans. , 2002, The Journal of clinical endocrinology and metabolism.

[89]  R. Ritter,et al.  Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[90]  B. Göke,et al.  Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[91]  C. Weyer,et al.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. , 2002, Diabetes care.

[92]  T. Lutz,et al.  Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[93]  G. Frost,et al.  Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[94]  R. Batterham,et al.  Ghrelin causes hyperphagia and obesity in rats. , 2001, Diabetes.

[95]  P. J. Larsen,et al.  Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. , 2001, Diabetes.

[96]  D. Smith,et al.  Oxyntomodulin inhibits food intake in the rat. , 2001, Endocrinology.

[97]  C. Beglinger,et al.  Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[98]  M. Nakazato,et al.  Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. , 2000, Endocrinology.

[99]  M. Tschöp,et al.  Ghrelin induces adiposity in rodents , 2000, Nature.

[100]  P. Kopelman Obesity as a medical problem , 2000, Nature.

[101]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[102]  M. Fujimiya,et al.  Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice☆ , 1999, Peptides.

[103]  J. Miyazaki,et al.  Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. , 1999, Gastroenterology.

[104]  M Morfis,et al.  Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.

[105]  W. F. Mathes,et al.  The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. , 1999, The Journal of clinical investigation.

[106]  J. Blundell,et al.  Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion , 1998, Physiology & Behavior.

[107]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[108]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[109]  F. Ehrensperger,et al.  Lesion of the Area Postrema/Nucleus of the Solitary Tract (AP/NTS) Attenuates the Anorectic Effects of Amylin and Calcitonin Gene-Related Peptide (CGRP) in Rats , 1998, Peptides.

[110]  K. Beaumont,et al.  Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. , 1997, Molecular pharmacology.

[111]  P. J. Larsen,et al.  Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. , 1997, Endocrinology.

[112]  R. M. Gentry,et al.  Comparison of Fos induced in rat brain by GLP-1 and amylin , 1997, Regulatory Peptides.

[113]  G. Schwartz,et al.  Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. , 1997, The American journal of physiology.

[114]  J. Rehfeld,et al.  Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. , 1996, Scandinavian journal of clinical and laboratory investigation.

[115]  P. J. Larsen,et al.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. , 1996, The American journal of physiology.

[116]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[117]  N. Geary,et al.  Amylin decreases meal size in rats , 1995, Physiology & Behavior.

[118]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[119]  G. Colditz,et al.  Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women , 1995, Annals of Internal Medicine.

[120]  A. Masclee,et al.  Satiety effects of a physiological dose of cholecystokinin in humans. , 1995, Gut.

[121]  J. Jansen,et al.  Satiety effects of cholecystokinin in humans. , 1994, Gastroenterology.

[122]  C. Beglinger,et al.  Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36 , 1994, Regulatory Peptides.

[123]  P. Mantyh,et al.  Cholecystokinin and neuropeptide Y receptors on single rabbit vagal afferent ganglion neurons: site of prejunctional modulation of visceral sensory neurons , 1994, Brain Research.

[124]  Daniel Grandt,et al.  Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV , 1993, Regulatory Peptides.

[125]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[126]  G. Berntson,et al.  Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome , 1993, Peptides.

[127]  J. Jansen,et al.  Effects of a physiological dose of cholecystokinin on food intake and postprandial satiation in man , 1993, Regulatory Peptides.

[128]  B. Thorens Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[129]  P. Blache,et al.  Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. , 1992, The Journal of clinical endocrinology and metabolism.

[130]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[131]  N. J. Andrews,et al.  Human gut hormone profiles in patients with short bowel syndrome , 1992, Digestive diseases and sciences.

[132]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[133]  L. Bednarz,et al.  Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats , 1992, Brain Research.

[134]  G. Cooper,et al.  Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. , 1991, Biochemical and biophysical research communications.

[135]  D. Whitcomb,et al.  Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. , 1990, The American journal of physiology.

[136]  D. Martin,et al.  Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. , 1990, Annals of surgery.

[137]  R. Rizza,et al.  Effects of Meal Ingestion on Plasma Amylin Concentration in NIDDM and Nondiabetic Humans , 1990, Diabetes.

[138]  G. Berntson,et al.  Short-term infusion of pancreatic polypeptide: effect on children with Prader-Willi syndrome. , 1990, The American journal of clinical nutrition.

[139]  Terry D. Lee,et al.  A new molecular form of PYY: Structural characterization of human PYY(3–36) and PYY(1–36) , 1989, Peptides.

[140]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[141]  D. Bataille,et al.  The effect of oxyntomodulin (Glucagon-37) and glucagon on exocrine pancreatic secretion in the conscious rat , 1987, Peptides.

[142]  L. Orci,et al.  Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.

[143]  J M Polak,et al.  Human distribution and release of a putative new gut hormone, peptide YY. , 1985, Gastroenterology.

[144]  J. Polak,et al.  Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[145]  J. E. Morley,et al.  Peptide YY (PYY), a poteny orexigenic agent , 1985, Brain Research.

[146]  D. Maclean Abrogation of peripheral cholecystokinin-satiety in the capsaicin treated rat , 1985, Regulatory Peptides.

[147]  I. Goldfine,et al.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. , 1985, The Journal of clinical investigation.

[148]  R. Ritter,et al.  Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin. , 1985, The American journal of physiology.

[149]  P S Kalra,et al.  Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. , 1984, Endocrinology.

[150]  S. Woods,et al.  Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. , 1984, The American journal of physiology.

[151]  W. Zipf,et al.  Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome. , 1983, The Journal of clinical endocrinology and metabolism.

[152]  S. Bloom,et al.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. , 1983, The Journal of clinical endocrinology and metabolism.

[153]  J. Crawley,et al.  Rapid development of tolerance to the behavioural actions of cholecystokinin , 1983, Nature.

[154]  G. Bell,et al.  Hamster preproglucagon contains the sequence of glucagon and two related peptides , 1983, Nature.

[155]  T. Blundell,et al.  Conformational flexibility in a small globular hormone: X‐ray analysis of avian pancreatic polypeptide at 0.98‐Å resolution , 1983, Biopolymers.

[156]  X. Pi-Sunyer,et al.  C-Terminal octapeptide of cholecystokinin decreases food intake in obese men , 1982, Physiology & Behavior.

[157]  D. Bataille,et al.  Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): A potent inhibitor of pentagastrin-stimulated acid secretion in rats , 1982, Bioscience reports.

[158]  G. Dockray,et al.  Regional distributions of somatostatin and cholecystokinin-like immunoreactivities in rat and bovine brain , 1981, Peptides.

[159]  W. Zipf,et al.  Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome. , 1981, The Journal of clinical endocrinology and metabolism.

[160]  G. Dockray,et al.  Neuropeptides in the gut: Quantification and characterization of cholecystokinin octapeptide-, bombesin- and vasoactive intestinal polypeptide-like immunoreactivities in the myenteric plexus of the guinea-pig small intestine , 1981, Peptides.

[161]  G. P. Smith,et al.  C-terminal octapeptide of cholecystokinin decreases food intake in man. , 1981, The American journal of clinical nutrition.

[162]  D. Bataille,et al.  ‘Enteroglucagon’: A specific effect on gastric glands isolated from the rat fundus. Evidence for an ‘oxyntomodulin’ action , 1981 .

[163]  R. McLeod,et al.  Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations. , 1980, Canadian journal of physiology and pharmacology.

[164]  G. Greenberg,et al.  Pharmacokinetics of pancreatic polypeptide in man. , 1978, Gut.

[165]  J. Holst,et al.  Vagal, cholinergic regulation of pancreatic polypeptide secretion. , 1978, The Journal of clinical investigation.

[166]  L. Orci,et al.  Pancreatic polypeptide: A possible role in the regulation of food intake in the mouse. Hypothesis , 1977, Experientia.

[167]  T. Adrian,et al.  Distribution and release of human pancreatic polypeptide. , 1976, Gut.

[168]  J. Polak,et al.  IDENTIFICATION OF CHOLECYSTOKININ-SECRETING CELLS , 1975, The Lancet.

[169]  G. P. Smith,et al.  Cholecystokinin decreases food intake in rats. , 1973, Journal of comparative and physiological psychology.

[170]  B. Zinman,et al.  Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus ( LEAD-4 Met + TZD ) , 2009 .

[171]  D. Dore,et al.  Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. , 2009, Current medical research and opinion.

[172]  J. Leahy A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes , 2007 .

[173]  K. Wynne,et al.  Attenuated peptide YY release in obese subjects is associated with reduced satiety. , 2006, Endocrinology.

[174]  S. Adams,et al.  PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. , 2006, The Journal of nutrition.

[175]  A. Sileno,et al.  Lower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3–36) in rabbits , 2006, International Journal of Obesity.

[176]  J. Leahy,et al.  Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§ , 2006 .

[177]  G. Tsujimoto,et al.  Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 , 2005, Nature Medicine.

[178]  Peter T. Katzmarzyk,et al.  Overweight and Obesity Mortality Trends in Canada, 1985–2000 , 2004, Canadian journal of public health = Revue canadienne de sante publique.

[179]  F. Sundler,et al.  Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells , 2004, Cell and Tissue Research.

[180]  P. Proost,et al.  Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. , 2003, Advances in experimental medicine and biology.

[181]  J. Rehfeld,et al.  The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. , 2001, The Journal of clinical endocrinology and metabolism.

[182]  J. Egan,et al.  Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. , 2000, Endocrinology.

[183]  T. Rink,et al.  Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. , 1996, Metabolism: clinical and experimental.

[184]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[185]  M. Wheeler,et al.  The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). , 1993, Endocrinology.

[186]  Graeme I. Bell,et al.  Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.

[187]  V. Mutt,et al.  Isolation of glucagon‐37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno‐ileum , 1982, FEBS letters.

[188]  R. Gates,et al.  The ability of pancreatic polypeptides (APP and BPP) to return to normal the hyperglycaemia, hyperinsulinaemia and weight gain of New Zealand obese mice. , 1977, Hormone research.

[189]  P. Brubaker,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .